Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | DC AML Vaccine |
Synonyms | |
Therapy Description |
DC AML vaccine is generated by fusing patient derived AML cells with autologous dendritic cells, resulting in anti-tumor immune response (PMID: 25625926, Blood 2013 122:3928). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DC AML Vaccine | DC AML vaccine is generated by fusing patient derived AML cells with autologous dendritic cells, resulting in anti-tumor immune response (PMID: 25625926, Blood 2013 122:3928). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03059485 | Phase II | DC AML Vaccine DC AML Vaccine + Durvalumab | DC/AML Fusion Cell Vaccine vs DC/AML Fusion Cell Vaccine Plus Durvalumab vs Observation in Patients Who Achieve a Chemotherapy-induced Remission | Completed | USA | 0 |